Challenges and Opportunities in HIVPractical Solutions Across the Spectrum of Care
Abdool Karim Q, Sibeko S, Baxter C. Clin Infect Dis. 2010;50(suppl 3):S122-S129.
Brief report: randomized, double-blind comparison of tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF), each coformulated with elvitegravir, cobicistat, and emtricitabine (E/C/F) for initial HIV-1 treatment: week 144 results.
Arribas JR, Thompson M, Sax PE, et al. J Acquir Immune Defic Syndr. 2017;75(2):211-218.
Improving care outcomes for PLWH experiencing homelessness and unstable housing: a synthetic review of clinic-based strategies.
Clemenzi-Allen AA, Hickey M, Conte M, et al. Curr HIV/AIDS Rep. 2020;17(3):259-267.
Coffey S, Halperin J, Rana AI, Colasanti JA. Clin Infect Dis. 2020. [Epub ahead of print]
Curtis KM, Tepper NK, Jatlaoui TC, et al. MMWR Recomm Rep. 2016;65(3):1-103.
Implementation of a rapid entry program decreases time to viral suppression among vulnerable persons living with HIV in the southern United States.
Colasanti J, Sumitani J, Mehta CC, et al. Open Forum Infect Dis. 2018;5(6):ofy104.
Eisinger RW, Dieffenbach CW, Fauci AS. JAMA. 2019;321(5):451-452.
Characteristics, prevention, and management of cardiovascular disease in people living with HIV: a scientific statement from the American Heart Association.
Feinstein MJ, Hsue PY, Benjamin LA, et al. Circulation. 2019;140(2):e98-e124.
Linkage and antiretroviral therapy within 72 hours at a Federally Qualified Health Center in New Orleans.
Halperin J, Butler I, Connor K, et al. AIDS Patient Care STDS. 2018;32(2):39-41.
A care continuum of immediate ART for newly diagnosed patients and patients presenting later to care at a Federally Qualified Health Center in New Orleans.
Halperin J, Conner K, Butler I, et al. Open Forum Infect Dis. 2019;6(4):ofz161.
Polypharmacy and drug-drug interactions in older and younger people living with HIV: the POPPY study.
Halloran MO, Boyle C, Kehoe B, et al. Antivir Ther. 2019;24(3):193-201.
Hoffmann C, Llibre JM. AIDS Rev. 2019;21(1):4-10.
Jaspal R, Kennedy L, Tariq S. Transgend Health. 2018;3(1):239-250.
The impact of comorbidities, depression, and substance use problems on quality of life among older adults living with HIV.
Millar BM, Starks TJ, Gurung S, Parsons JT. AIDS Behav. 2017;21(6):1684-1690.
Nasi M, De Biasi S, Gibellini L, et al. Clin Exp Immunol. 2017;187(1):44-52.
The effect of same-day observed initiation of antiretroviral therapy on HIV viral load and treatment outcomes in a US public health setting.
Pilcher CD, Ospina-Norvell C, Dasgupta A, et al. J Acquir Immune Defic Syndr. 2017;74(1):44-51.
Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials.
Sax PE, Erlandson KM, Lake JE, et al. Clin Infect Dis. 2020;71(6):1379-1389.
Current challenges and solutions in research and clinical care of older persons living with HIV: findings presented at the 9th International Workshop on HIV and Aging.
Sundermann EE, Erlandson KM, Pope CN, et al. AIDS Res Hum Retroviruses. 2019;35(11-12):985-998.
Wing EJ. Int J Infect Dis. 2016;53:61-68.
Vachiat A, McCutcheon K, Tsabedze N, Zachariah D, Manga P. J Am Coll Cardiol. 2017;69(1):73-82.
Zash R, Holmes L, Diseko M, et al. J Int AIDS Soc. 2020;23(suppl 4):183-184. Abstract OAXLB0102.
The PCPs Role in Preventing HIV
What Do You Know About PrEP?
Optimizing Use of Clinical Evidence & Pharmacoeconomic Models in Managed Care
What Do You Know About PrEP?
Got it? Treat it!
The Critical Role of the Community Pharmacist
Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.
Volume 1: Rapid ART Initiation: A New Addition to the HIV-Care Tool Box
Key Issues Impacting OB/GYN Practice
Hot Topics in HBV, HCV, and NASH
Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice
Why It Matters in OB/GYN Practice Today
A Treater’s Guide to Optimizing Care in the Aging Patient with Comorbidities
How the Pharmacist Can Make a Difference
HIV Can Be Prevented— Are You Doing Your Part?
Rapid Start ART — A New Model for HIV Care
Understanding the Growing Syndemic — Opioids, HCV, and HIV
A PrEP Primer
The PCP’s Role in HCV Elimination
What the Pharmacist Needs to Know about PrEP
The Rapid ART Standard of Care: From Evidence to Healthcare Equity
Maximizing Your Role to Impact Patient Outcomes
Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV
Benefits, Barriers, & Best Practices in an Advancing Field
A PEP/PrEP Training Guide for Pharmacists
A Critical Step Toward HCV Elimination
Considering the Patient, the Provider, and the Science
A Multidisciplinary Online Mini-Curriculum
Debates and Discussions about Monoclonal Antibody Therapies
An Update on Monoclonal Antibody Therapies
Establishing Clinical Readiness Through Mentored Learning
Recent Developments in Anti-SARS-CoV-2 Monoclonal Antibodies for Treatment
An Update on Best Practices
New Avenues to Pre-Exposure Prophylaxis
An Updated Clinician’s Guide to Assessment and Management
What the Pharmacist Needs to Know
A Look at the Changing HIV Playing Field
A “How To” Series Spanning Policy to Practice
Test Your Mastery!
Building Bridges to Reach People who Inject Drugs with the Goal of Employing PrEP for HIV Prevention
Bringing HIV Prevention to a New Level
Optimizing HIV Prevention in Primary Care
Monoclonal Antibodies for the Prevention and Treatment of COVID-19
A Phone-a-Friend CME Series – Volume 2
Incorporating New Data and Updated Guidelines Into Daily Practice